Thursday, July 02, 2020 10:54:58 AM
Retail
Wholesale
Aegea test kit
And the drug trial. I imagine that getting all the ducks in a row with SEC.
I don’t think this will be a long trial if safety data can be piggybacked off approved CBD drug. Patients will know in a matter of a couple weeks whether this helps with nausea or not.
VTGN has gotten more interesting for TAUG also. I think TAUG controls well over 1 million shares when you factor in warrants that are exercisable are .50.
If VTGN does a few more joint ventures like they just announced this will get very interesting. China/Korea is second biggest drug market. VTGN just licensed a phase 3 ready nasal Social anxiety drug for a $5 mil up front non dilutive payment with $172 mil in milestone payments through various points of phase 3 trial. Plus the trial is fully paid for and if successful double digit royalties.
And while the AV 101 missed its 2b endpoint, it looks like a new patent is established using a combination drug to get more drug converted through the blood Breslin barrier. This is the same technique AXSM used when it was trading at $2.00.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM